DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

AstraZeneca Pharma India Limited — Outcome of Board Meeting

NSE 1 hr ago·10 Aug 2026, 8:26 am

AstraZeneca Pharma India

AstraZeneca Pharma India Limited has informed stock exchanges that its board has approved the financial results for the period ending June 30, 2026. This announcement confirms that the company has completed the filing of its quarterly financial statements with the relevant authorities.

For investors, this update is a standard procedural step that signals the company's compliance with regulatory requirements. It provides a scheduled timeline for the release of detailed financial data, which is typically followed by an investor presentation and a conference call to discuss performance metrics.

Investors should wait for the detailed results and management commentary to assess the company's operational health and growth trajectory. Key areas of focus will include sales performance, profitability, and any strategic initiatives announced during the subsequent disclosure.